Complement system on the attack in autoimmunity.
Level V
Where this comes from
- Record sourced from PubMed, PMID 14660739.
- Also identified by PMC identifier 281650.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The antiphospholipid syndrome is characterized clinically by fetal loss and thrombosis and serologically by the presence of autoantibodies to lipid-binding proteins. In a model of this procoagulant condition in which these antibodies are injected into pregnant mice, fetal loss was prevented by blocking of complement activation. Specifically, interaction of complement component 5a (C5a) with its receptor is necessary for thrombosis of placental vasculature. Inhibition of complement activation may have a therapeutic role in this disease.
Medical subject headings
- Abortion, Spontaneous
- Antiphospholipid Syndrome
- Neutrophils
- Pregnancy Complications
- Receptor, Anaphylatoxin C5a